Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007943 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine in Treating Patients With Advanced Colorectal Cancer
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00007943 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 15 participants.
The verdict
NCT00007943, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have advanced colorectal cancer.
Interventions
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2000-09-01 |
| Est. Completion | 2001-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00007943
The ClinicalTrials.gov registry entry for NCT00007943 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gemcitabine hydrochloride is the first listed.
NCT00007943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00007943 about?
NCT00007943 is a clinical study titled "Gemcitabine in Treating Patients With Advanced Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have advanced colorectal cancer.
What is the current status of trial NCT00007943?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2000-09-01. Estimated completion is 2001-02-27.
What interventions are being tested in trial NCT00007943?
The interventions under investigation include: gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00007943?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.